Getting R&D Right: NASEM Panel Weighs Strategies To Match Innovation With Disease Burden

A US National Academy of Sciences, Engineering and Medicine panel is considering whether biomedical innovation is aligned with public health needs. The resulting report could impact FDA and federal policy on rare disease and research and development incentives.

incentives aligned
Incentives exist, but are not coordinated, Scott Howell said during a NASEM meeting on the subject. • Source: Shutterstock

US Food and Drug Administration Commissioner Robert Califf has emphasized the key public health paradox that in an era of unprecedented biomedical innovation, the country still faces an incredibly high chronic disease and early mortality burden.

Key Takeaways
  • A NASEM committee is researching whether drug development incentives and investments are aligned with unmet needs and disease burden.

  • The upcoming report could impact FDA rare disease and other incentives, as well as allow industry to seek more incentives for development in common diseases

“It is a conundrum,” Califf said during the 7 October meeting of the FDA’s Science Board. “We are leading the world. Everywhere I go, people are in awe of the innovation in the US. But we are continuing to lose ground compared to other high-income countries in our health status

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Pink Sheet

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.